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Isolated tumor cells in stage I & II colon
cancer patients are associated with
significantly worse disease-free and overall
survival
B. Weixler1,6, R. Warschkow2,7, U. Güller3,4, A. Zettl5, U. von Holzen6, B. M. Schmied2 and M. Zuber1*
Abstract
Background: Lymph node (LN) involvement represents the strongest prognostic factor in colon cancer patients.
The objective of this prospective study was to assess the prognostic impact of isolated tumor cells (ITC, defined as
cell deposits ≤ 0.2 mm) in loco-regional LN of stage I & II colon cancer patients.
Methods: Seventy-four stage I & II colon cancer patients were prospectively enrolled in the present study. LN at
high risk of harboring ITC were identified via an in vivo sentinel lymph node procedure and analyzed with
multilevel sectioning, conventional H&E and immunohistochemical CK-19 staining. The impact of ITC on survival
was assessed using Cox regression analyses.
Results: Median follow-up was 4.6 years. ITC were detected in locoregional lymph nodes of 23 patients (31.1 %).
The presence of ITC was associated with a significantly worse disease-free survival (hazard ratio = 4.73, p = 0.005).
Similarly, ITC were associated with significantly worse overall survival (hazard ratio = 3.50, p = 0.043).
Conclusions: This study provides compelling evidence that ITC in stage I & II colon cancer patients are associated
with significantly worse disease-free and overall survival. Based on these data, the presence of ITC should be
classified as a high risk factor in stage I & II colon cancer patients who might benefit from adjuvant chemotherapy.
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Background
Colon cancer still remains one of the leading causes of
cancer related death and represents a tremendous public
health problem. The TNM staging system discriminates
nodal negative (stage I & II) from nodal positive (stage III)
disease. Adjuvant treatment is usually reserved to stage III
disease. It is assumed that complete surgical resection can
be achieved in stage I & II colon cancer and therefore no
further treatment is recommended for most of these
patients. Unfortunately, up to 20 % of stage I & II disease
patients will develop recurrence within five years after
diagnosis. The cause of this high recurrence rate remains
unclear [1, 2]. However, the identification of factors
predicting a worse survival in stage II colon cancer led the
American Society of Clinical Oncology (ASCO) [3–5], the
Nationonal Comprehensive Cancer Network (NCCN) and
the European Society for Medical Oncology (ESMO) to
define a collective of high-risk patients who may benefit
from adjuvant chemotherapy. Those high-risk stage II
colon cancer patients feature at least one of the follwing
characteristics: pT4 tumor, poorly differentiated hist-
ology, presence of lymphovascular invasion, localized
perforation, bowel obstruction or less than 12 lymph
nodes (LN) analyzed [4, 6]. The patient benefit of an ad-
juvant treatment in this subgroup, however, remains a
matter of debate [7].
While uncertainty persists regarding the explanation
of the high recurrence-rate in node negative colon can-
cer, there is emerging evidence that the appearance of
isolated tumor cells (ITC) and micro-metastases in LN
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could be associated with worse prognosis [8–14]. Ac-
cording to the TNM classification system micro-
metastases are defined as tumor deposits of 0.2 mm
to ≤ 2 mm in diameter, labeled as pN1(mi), and ITC as
either single tumor cells or clusters of tumor cells of
0.2 mm or less, labeled as pN0(i+) [15].
The worldwide standard of histopathologic analysis of
colon cancer LN represents a single-level sectioning and
hematoxylin-eosin (H&E) staining through each discovered
LN. However, this method provides a very limited access to
the examined tissue and implies a relevant risk of sampling
bias and understaging [16]. Indeed, the detection of ITC
usually requires either molecular methods [17] or step sec-
tioning combined with immunohistochemistry and hence,
ITC are often missed using standard H&E staining. There-
fore, a few research groups have been evaluating the senti-
nel lymph node (SLN) procedure in colon cancer to allow a
more thorough investigation of a few LN with high prob-
ability of hiding tumor infiltrates. SLN assessment has been
reported to lead to an upstaging of up to 15 % of patients
with initially node negative colon cancer [16, 18–20].
There is rising evidence that colon cancer patients
with micro-metastases will have a prognosis similar to
patients with macro-metastases but little has been pub-
lished about the prognostic impact of ITC. Furthermore,
the vast majority of published studies are either retro-
spective or do not differentiate between colon and rectal
cancer [8, 21, 22]. To date only seven studies exist which
investigate the influence of ITC in node negative colon
cancer [12].
Therefore, the objective of our prospective study was
to asses the prognostic impact of ITC on disease-free
and overall survival in stage I & II colon cancer patients.
Methods
This study was performed between January 2005 and
December 2012 in an university affiliated hospital
(Kantonsspital Olten) and was designed as a prospective
single center trial. The study was approved by the ethics
committee EKNZ (Ethikkommission Nordwest- und
Zentralschweiz) and all patients had given written in-
formed consent prior to surgery.
Patients undergoing primary resection for histologi-
cally proven colon cancer were admitted to open
surgery and - after providing written informed consent -
analyzed according to the Swiss SLN protocol. This pro-
cedure consists of the in-vivo peritumoral injection of
isosulfan blue to identify the SLN, a procedure de-
scribed in detail elsewhere [19]. Only node negative
colon cancer patients, i.e. pN0 (stage I & II) were in-
cluded in this study. A total of 74 patients could be ana-
lyzed. Patients were divided into two groups, patients in
whom ITC were detected and patients who were truly
node negative.
Histopathologic examination
Five serial sections were obtained at 3 different levels of
each marked SLN. H&E staining was then performed for
the first section of each level. If no metastatic deposits
were detected, an immunohistochemical staining with
AE1/AE3 or CK19 was conducted for the fourth section
of each level. To collect the remaining non-SLN, the
fixed specimen was then manually dissected. Bivalving
and H&E staining of the non-SLN were then carried out.
All cytokeratin positive cells were confirmed to be
tumor cells, based on morphological characteristics, by
microscopic reevaluation of the immunostained sections
after counterstaining with hemalaun.
Staging
After completion of the study in December 2012, all histo-
pathologic reports were reviewed and staging was then per-
formed according to the 7th edition of the UICC staging
manual [23]. Isolated tumor cell deposits ≤ 0.2 mm were
considered as ITC [15, 24]. Patients in whom ITC were de-
tected after the above described histopathological in-depth
analyses were staged as pN0(i+).
Data collection and definitions
Survival and disease recurrence data were obtained by
phone interview with the responsible oncologist and/or
general practitioner. Adjuvant chemotherapy was given ac-
cording to interdisciplinary tumor board decisions. This de-
cision was made individually for each patient and was
based on the presence of high risk factors (T4, lymphovas-
cular invasion, poor differentiation, etc.) and the patient’s
general condition. ITC were not considered as an indication
for adjuvant chemotherapy.
Statistical analyses
Statistical analyses were performed using the R statistical
software (www.r-project.org). A two-sided p-value < 0.05
was considered statistically significant. Continuous data
are expressed as means ± standard deviations. For
comparing proportions, Chi-Square statistics and for
comparing continuous variable t-tests were used.
Disease-free survival was defined as the primary out-
come variable.
First, the risk for ITC was assessed regarding age, gen-
der, tumor localization, tumor staging, grading, lympho-
vascular invasion, preoperative CEA levels, number of
extracted lymph nodes, number of sentinel lymph nodes,
and adjuvant therapy. The same set of covariates includ-
ing ITC were then assessed as putative prognostic fac-
tors for disease-free and overall survival in unadjusted
and risk-adjusted Cox regressions including a backward
variable selection procedure from the full Cox regression
model based on the Akaike’s information criterion.
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The relative survival – as a validated mean to re-
flect the cancer-specific survival – was estimated
[25]. Relative survival was calculated as the ratio of
the observed overall survival rate and the expected
population-based survival rate (“background mortal-
ity”) [26]. The population tables regarding back-
ground mortality for the relative survival analyses
were obtained from the Swiss National Statistical Of-
fice [27]. The relative survival analyses were con-
ducted using the R package “relsurv” using the
Pohar-Perme-estimator [28]. Population mortality
rates were included as time-dependent covariates in
multiplicative Cox regression model [29].
Results
Patient characteristics and propensity for detection of ITC
A total of 74 patients with a median follow-up time of
4.6 years (range:1 month to 8.0 years) were eligible for
the present analysis. On average, 28.5 ± 11.7 LN were
resected with an average of 5.8 ± 3.4 SLN. In 23 of the
74 stage I & II patients (31.1 %) ITC were detected.
Table 1 summarizes the patient characteristics and the
outcomes. Differences between patients with and without
ITC did not reach the significance level except the use of
adjuvant therapy (Table 1). In univariate and multivariable
logistic regression, adjuvant therapy again was the only
variable independently associated with the detection of
Table 1 Patient characteristics and outcome for stage I & II colon cancer patients
Patient characteristics Total N = 74 ITC N = 23 No ITC N = 51 p
Age (Years) 70.6 ± 11.4 69.3 ± 10.2 71.2 ± 11.9 0.494 A)
Gender Male 39 (52.7 %) 13 (56.5 %) 26 (51.0 %) 0.659 B)
Female 35 (47.3 %) 10 (43.5 %) 25 (49.0 %)
Tumor localisation Colon caecum 12 (16.2 %) 1 (4.3 %) 11 (21.6 %) 0.084 B)
Ascending colon 16 (21.6 %) 5 (21.7 %) 11 (21.6 %)
Transverse colon 13 (17.6 %) 4 (17.4 %) 9 (17.6 %)
Descending colon 7 (9.5 %) 5 (21.7 %) 2 (3.9 %)
Rectosigmoid colon 26 (35.1 %) 8 (34.8 %) 18 (35.3 %)
T-stage I 7 (9.5 %) 0 (0.0 %) 7 (13.7 %) 0.264 B)
II 21 (28.4 %) 7 (30.4 %) 14 (27.5 %)
III 42 (56.8 %) 14 (60.9 %) 28 (54.9 %)
IV 4 (5.4 %) 2 (8.7 %) 2 (3.9 %)
Grading I 1 (1.4 %) 0 (0.0 %) 1 (2.0 %) 0.792 B)
II 47 (63.5 %) 15 (65.2 %) 32 (62.7 %)
III 26 (35.1 %) 8 (34.8 %) 18 (35.3 %)
Lymphovascular No 63 (85.1 %) 17 (73.9 %) 46 (90.2 %) 0.091 C)
invasion Yes 11 (14.9 %) 6 (26.1 %) 5 ( 9.8 %)
Preoperative CEA <5 μg/l 59 (79.7 %) 16 (69.6 %) 43 (84.3 %) 0.167 C)
levels ≥5 μg/l 15 (20.3 %) 7 (30.4 %) 8 (15.7 %)
TotalLNn (n) 28.6 ± 11.7 27.7 ± 11.5 29.0 ± 11.9 0.668 A)
SLNn (n) 5.8 ± 3.4 6.0 ± 3.5 5.6 ± 3.4 0.685 A)
NSLNn (n) 22.9 ± 11.6 21.7 ± 10.6 23.4 ± 12.1 0.565 A)
Adjuvant therapy No 65 (87.8 %) 17 (73.9 %) 48 (94.1 %) 0.025 C)
Yes 9 (12.2 %) 6 (26.1 %) 3 (5.9 %)
Recurrence No 71 ( 95.9 %) 21 (91.3 %) 50 ( 98.0 %) 0.254 C)
Yes 3 (4.1 %) 2 (8.7 %) 1 (2.0 %)
Yes: liver 1 (1.4 %) 0 (0.0 %) 1 (2.0 %)
Yes: lung 2 (2.7 %) 2 (8.7 %) 0 (0.0 %)
Death No 58 (78.4 %) 16 (69.6 %) 42 (82.4 %) 0.239 C)
Yes 16 (21.6 %) 7 (30.4 %) 9 (17.6 %)
n (%); mean ± standard deviation
A) t-Test, B) Chi-squared test, C) Mid-p test
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ITC (odds ratio = 5.65, 95 % CI = 1.34 to 29.2). The nine
patients who received adjuvant therapy did have stage II
colon cancer and all of them featured at least one high risk
factor. These nine patients were younger (62.8 ± 13.8 years
vs. 71.7 ± 10.7 years, p = 0.093), had more advanced tumor
stages (AJCC stage II in 9 out of 9 patients vs. 37 of 65
patients, p = 0.010), had more often a lymphovascular
invasion (4 of 9 patients vs. 7 of 65 patients, p = 0.026),
and had more frequently elevated preoperative CEA levels
(4 of 9 patients vs. 11 of 65 patients, p = 0.090).
ITC as a prognostic factor for disease-free survival
An unadjusted Cox proportional hazards regression
analysis revealed ITC as a prognostic factor for disease-
free survival with an approximately 182 % increased risk
for recrurrence (hazard ratio (HR) of death = 2.82, 95 %
CI = 1.06 to 7.49, p = 0.043) (Table 2). The five-year
disease-free survival for patients with ITC was 63.4 %
(95 % CI = 43.0 % to 93.4 %) compared to 89.6 % (95 %
CI = 81.3 % to 98.7 %) in patients without ITC (Fig. 1).
After adjusting for potential confounders in multivariable
Cox regression analyses, ITC remained associated with a
worse disease-free survival (HR = 3.69, 95 % CI = 1.18 to
10.9, p = 0.024). Moreover, a backward variable selection
procedure revealed ITC as an independent factor for
higher risk of recurrence (HR = 4.73, 95 % CI = 1.67 to
13.4, p = 0.005).
ITC as a prognostic factor for overall survival
Unadjusted Cox proportional hazards regression analysis
did not reveal ITC as a statistically significant prognostic
factor for overall survival (HR of death = 2.27, 95 % CI =
0.83 to 6.17, p = 0.119). ITC were an independent signifi-
cant prognostic factor for overall survival after risk-
adjusting in multivariable Cox regression analysis (HR of
death = 3.50, 95 % CI = 1.03 to 11.8, p = 0.043) and in
backward variable selection (hazard ratio of death = 4.48,
95 % CI = 1.50 to 13.4, p = 0.010) (Fig. 2).
ITC as a prognostic factor for relative survival
A Cox proportional hazards regression analysis with
adjustment for the population-based background mor-
tality revealed ITC as a significant poor prognostic fac-
tor for relative survival (hazard ratio of death = 3.31,
Table 2 Prognostic factors for disease-free survival after colon cancer resection
Prognostic factors Cox Regression
Unadjusted A) Full model B) Variable selection C)
HR (95 % CI) p D) HR (95 % CI) p D) HR (95 % CI) p D)
ITC No Reference 0.043 Reference 0.024 Reference 0.005
Yes 2.82 (1.06–7.49) 3.59 (1.18–10.9) 4.73 (1.67–13.4)
Age (years) 1.10 (1.03–1.17) 0.001 1.12 (1.03–1.22) <0.001 1.13 (1.05–1.21) <0.001
Gender male Reference 0.260 Reference 0.220 - -
female 0.57 (0.21–1.55) 0.51 (0.17–1.53) - -
Tumor localisation colonic Reference 0.428 Reference 0.886 - -
rectosigmoidal 0.64 (0.21–2.00) 0.91 (0.24–3.47) - -
AJCC stage I Reference 0.569 Reference 0.581 - -
II 1.35 (0.47–3.84) 1.39 (0.43–4.52) - -
Grading GI/GII Reference 0.356 Reference 0.952 - -
GIII 1.62 (0.57–4.62) 1.04 (0.28–3.84) - -
Lymphovascular No Reference 0.182 Reference 0.368 - -
invasion Yes 2.30 (0.74–7.12) 2.04 (0.45–9.31) - -
Preoperative CEA <5 μg/l Reference 0.304 Reference 0.302 - -
levels ≥5 μg/l 0.49 (0.11–2.15) 0.42 (0.07–2.44) - -
TotalLNn (n) 0.98 (0.94–1.02) 0.323 1.00 (0.95–1.05) 0.898 - -
SLNn (n) 1.00 (0.86–1.15) 0.954 1.02 (0.85–1.22) 0.850 - -
Adjuvant No Reference 0.976 Reference 0.705 - -
Chemotherapy Yes 0.98 (0.22–4.33) 1.47 (0.21–10.4) - -
HR - Hazard ratios with 95 % confidence intervals (Wald type)
Prognostic factors for overall survival in
A) one Cox proportional hazards regression analyses for each factor
B) Cox proportional hazards regression analyses for all factors
C) Cox proportional hazards regression analyses after backwards variable selection
D) p values for likelihood ratio test
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95 % CI = 1.22 to 9.03, p = 0.025). When further adjust-
ing for other confounders in multivariable analysis,
ITC remained a significant poor prognostic factor for rela-
tive survival (hazard ratio of death = 3.83, 95 % CI = 1.12
to 13.1, p = 0.032). For patients without ITC, the relative
survival did not significantly exceed the survival one
would expect for the Swiss population matched for age,
gender and year of operation (p = 0.950). However, for pa-
tients with ITC, the survival was significantly worse when
comparing with the Swiss population matched for age,
gender and year of operation (p = 0.001). For patients
without ITC, nine deaths were recorded (9/51, 17.6 %),
three occurred due to tumor recurrence (3/51, 5.9 %).
For patients with ITC, seven deaths were recorded (7/
23, 30.4 %), two occurred because of tumor recurrence
(2/23, 8.7 %).
Discussion
The present study provides compelling evidence that ITC
have a significant negative impact on both disease-free
and overall survival in stage I&II colon cancer patients.
LN involvement represents the most important prog-
nostic factor in colon cancer patients [24, 30, 31]. Despite
complete surgical resection and the call for a minimum of
12 analyzed LN for adequate staging, an unsettling high
recurrence rate in stage I & II colon cancer patients re-
mains. Based on the present study it appears that this dis-
turbing phenomenon can at least partially be explained by
small lymph node tumor infiltrates that are missed during
standard histopathological analyses.
In accordance with our data there is an increasing body
of evidence that immunohistochemical and molecular
tumor cell detection identifies patients with poorer prog-
nosis [8, 10–12]. It appears that the conventional patho-
logic LN assessment with H&E staining, as proposed by
the College of American Pathologists, is not sufficient
[32]. It is a logical consequence that a more in depth ana-
lysis of LN with the highest probability of harbouring ITC
(the sentinel lymph nodes) would reflect more accurately
the real tumor burden. Based on these considerations the
SLN mapping procedure in colon cancer has been advo-
cated by different research groups in Europe as well as
North America [16, 18–20, 33]. In the present study all
prospectively included patients were analyzed according
to a standardized SLN protocol using immunohistochem-
istry to identify ITC. The present investigation clearly
demonstrates a negative prognostic impact of ITC in SLN
on disease-free survival. Furthermore, ITC was a poor
prognostic factor for overall survival in risk adjusted Cox
regression analyses.
Comparing data from different studies requires a uni-
form system of classifying small nodal tumor infiltrates.
However, the use of an inconsistent nomenclature in
many studies renders a comparison among published
studies difficult [8, 10, 22]. The TNM staging system de-
fines single tumor cells or tumor cell clusters ≤ 0.2 mm
as ITC which are pathologically classified as pN0(i+)
[24]. In our series, the prevalance of pN0(i+) patients
was 31 % and confirms the average detection rate of
Fig. 1 Kaplan–Meier curve for disease-free survival in unadjusted analysis.
The number of colon cancer patients at risk are given below each plot
Fig. 2 Kaplan–Meier curve for overall survival in unadjusted analysis
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most other studies using immunohistochemistry [8, 11,
12, 14, 18, 20].
As an indicator for surgical quality and pathological
thoroughness a minimum of 12 resected LN are re-
quired for adequate colon cancer staging. An average
of 28.5 ± 11.7 resected LN and 5.8 ± 3.4 collected SLN
reflect an excellent quality of oncological resection and
pathological dissection. This may also reflect the rela-
tively low recurrence rate of 4.1 % of our patients after
a median follow up of 4.6 years.
In this study we report on a collective of 74 stage I &
II colon cancer patients. Most previously published
studies did not differentiate between colon and rectal
cancer [10, 16, 21]. However, staging, therapeutic regi-
mens, prognosis and even recurrence patterns differ
between colon and rectal cancer. We thus advocate
that the two tumor types should be considered as dif-
ferent diseases and analysed separately.
We would like to acknowledge the limitations of the
present investigation. First, this analysis is a cohort study
and not a randomized controlled trial. However, for the re-
search question at hand, it is simply not possible to perform
a randomized trial. Second, potential bias due to unknown
confounding cannot be completely excluded. And finally,
the patient number was rather low, probably explaining the
lack of a significant result for the association between ITC
and overall survival in unadjusted risk analysis. However,
the disadvantageous effect of ITC persisted after risk-
adjustment both for overall and disease-free survival. More-
over, this study is among the largest to investigate the prog-
nostic impact of ITC on disease-free and overall survival.
The current ASCO, NCCN and ESMO guidelines rec-
ommend adjuvant chemotherapy for stage II patients
featuring high risk factors for tumor recurrence [3–5].
The patients in the presented trial did not receive adju-
vant chemotherapy unless the above-mentioned criteria
were present. The question if adjuvant treatment should
be offered to the subgroup of ITC positive patients was
beyond the scope of our study, however, it is likely that
such patients do benefit from adjuvant chemotherapy.
Conclusions
This study provides compelling evidence that ITC are an
independent poor prognostic factor for disease-free and
overall survival and pN0(i+) colon cancer should therefore
be considered as a high risk factor. Hence, the identification
of true node negative patients, which are cured by surgical
resection alone, should be considered in future studies and
guidelines.
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